or Try an Advanced Search...

    Solid Tumors Stocks List

    Symbol Grade Name % Change
    KYMR D Kymera Therapeutics, Inc. -1.23
    INAB D IN8bio, Inc. -0.47
    CLDI D Calidi Biotherapeutics, Inc. -6.11
    SLS D SELLAS Life Sciences Group, Inc. -1.61
    PSTX D Poseida Therapeutics, Inc. -0.37
    CASI D CASI Pharmaceuticals, Inc. -0.19
    MRKR D Marker Therapeutics, Inc. -7.18
    ARWR D Arrowhead Research Corporation -2.30
    MEIP D MEI Pharma, Inc. 0.36
    THAR D Tharimmune, Inc. 4.40
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
    Related Stock Lists: Cancer Biotechnology Biopharmaceutical Clinical Medicine Medicine Cancer Immunotherapy Immune System Immunotherapy Biology Cancer Therapies Cancer Treatment Cell Therapy Immunotherapies Treatment Of Cancer Tumor Virotherapy Abdominal Pain Adoptive Cell Transfer Akseli Hemminki Anaplastic Lymphoma Kinase

    Related ETFs - A few ETFs which own one or more of the above listed Solid Tumors stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 4.73
    IDNA D iShares Genomics Immunology and Healthcare ETF 4.42
    CNCR F Loncar Cancer Immunotherapy ETF 3.2
    SBIO C ALPS Medical Breakthroughs ETF 3.19
    WDNA D WisdomTree BioRevolution Fund 2.33
    View all Solid Tumors ETFs...
    Compare ETFs
    Compare CNCR to SBIO Compare GNOM to IDNA Compare SBIO to WDNA

        Solid Tumors Stocks Recent News

        Date Stock Title
        Nov 18 THAR Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
        Nov 18 ARWR Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
        Nov 18 ARWR Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
        Nov 17 MRKR Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 17 MEIP Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 16 SLS We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
        Nov 15 CASI CASI Pharmaceuticals reports Q3 results
        Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Devices Other Shell Companies
        Related Stock Lists: Cancer Biotechnology Clinical Medicine Medicine Biopharmaceutical Cancer Immunotherapy Cancer Treatment Cell Biology Cell Therapy Leukemia Lymphoma Multiple Myeloma Acute Myeloid Leukemia Advanced Solid Tumors Antineoplastic Drugs Apoptosis Drugs Organ Systems Ovarian Cancer Pharmaceutical
        Solid Tumors

        Solid tumors are masses of abnormal cells that form when cells in the body divide and grow uncontrollably. They are usually found in the organs, but can also form in the tissues of the body. Solid tumors can be benign (non-cancerous) or malignant (cancerous).

        Browse All Tags